Guidance for Industry and Food and Drug Administration; Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements; Availability, 194-196 [07-6268]
Download as PDF
<![CDATA[
pwalker on PROD1PC71 with NOTICES
194
Federal Register / Vol. 73, No. 1 / Wednesday, January 2, 2008 / Notices
including policies involving food
derived from biotechnology.
Advises Center officials on regulatory
approaches and manages the
development of periodic plans for the
Center’s regulation development
activities.
Develops legislative proposals related
to food and cosmetic safety and defense;
coordinates the Center’s review of bills
and proposed legislation, upon request;
and coordinates the Center’s technical
assistance to Congressional or FDA
Office of Legislation staff developing
bills related to food and cosmetics, upon
request.
Manages the Center’s compliance
with the Information Quality Act,
including responses to request for
correction and reconsideration
submitted under the Act.
Advises Center staff concerning the
administrative procedures for
rulemaking, guidelines, guidance
documents, and other policy
documents, hearings and delegations of
authority.
Leads the Center’s evaluation of
existing regulations to determine
whether they are efficiently or
effectively accomplishing their intended
purpose.
Provides Center-level leadership and
coordination regarding briefings with
other parts of the Agency or Federal
Government with clearance
responsibility regarding CFSAN
regulations and guidance documents,
and other CFSAN documents subject to
the Paperwork Reduction Act, in
coordination with the Executive
Operations Staff.
Directs and manages Center programs
involving the use of external scientific
advisors, consultants, and committees.
Counsels and coordinates with Center
managers on the use of external
scientific experts and resources.
N. OFFICE OF NUTRITION,
LABELING, AND DIETARY
SUPPLEMENTS (DHK). The Office of
Nutrition, Labeling, and Dietary
Supplements (ONLDS):
Primary responsibility for policy
development and management of food
and nutrition labeling, food standards,
conventional foods, dietary
supplements, and special nutritional
(including infant formula and medical
foods) food.
Provides expert advice to the Center
Director, other Deputy Directors, and
other senior managers, and directs major
Agency and Department nutrition and
labeling initiatives and is the Delegate to
national and international forums and
conferences.
Primary responsibility for policy and
regulatory development and
VerDate Aug<31>2005
19:55 Dec 31, 2007
Jkt 214001
management of the food labeling
program, including Nutrition Labeling
and Education Act, Food Allergen
Labeling and Consumer Protection Act
and other Federal Food, Drug, and
Cosmetic Act and Fair Packaging and
Labeling Act labeling requirements.
Provides scientific and technical
review of and response to petitions and
notifications related to all aspects of
conventional food labeling. With the
Office of Compliance, determines
compliance with existing food standards
and common or usual name regulations
and issues temporary marketing permits
to allow manufacturers to test market
new foods. In addition, conducts
scientific and technical review of
enforcement and compliance materials
including inspection reports, analytical
reports and other pertinent records, and
provides policy decisions on
misbranding charges for all domestic
and import actions, including infant
formula and medical food
manufacturers.
Provides expert guidance for other
Agency units and Federal and State
officials and industry concerning
regulatory requirements and compliance
policies on food labeling (including
infant formula and medical foods) and
reviews proposed enforcement/
compliance actions referred by other
agency units.
Provides expert technical advice for
participation in international forums.
Reviews food product labeling
(including infant formula, medical foods
and nutrition labels) for adherence to
regulations and appropriateness of
claims and manages the Small Business
Nutrition Labeling Exemption
Notification Program.
Provides scientific review and
analysis of policies, regulations,
research priorities, position papers, and
advisory opinions on issues related to
nutrition and nutrition labeling, and
dietary guidance recommendations, and
related nutrition science issues.
Responsible for scientific and
regulatory review of health claim
petitions, qualified health claim
petitions, nutrient content claim
petitions, and FDA Modernization Act
notifications for health claims and
nutrient content claims.
Provides expert advice and assistance
to key officials and coordinates with
other domestic and international
scientific bodies on efforts related to
nutrition and health.
Identifies program priorities for,
provides content design input to, and
analysis of large-scale databases of food
consumption, food composition, food
ingredients, sales of processed packaged
food products and product label
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
information. Develops methods for
monitoring US populations and special
subgroups relative to use and safety of
conventional foods and dietary
supplements.
Provides management and scientific
review on issues related to infant
formula, medical foods, and dietary
supplements including petitions and
notifications, and provides advice to key
Agency components as well as
international bodies.
Responsible for the development of
regulations, guidance, policy, programs,
position papers and advisory opinions,
and recommends research priorities for
the management of the dietary
supplement program, which includes
safety assessments for the New Dietary
Ingredient Notification Program,
structure-function notifications,
Certificates of Export, safety assessment
for dietary supplement policy,
responses to petitions and industryrelated notifications, post-market
adverse event evaluations, and issues
related to dietary supplement safety and
nutrition.
III. Delegations of Authority. Pending
further delegation, directives, or orders
by the Commissioner of the Food and
Drugs, all delegations or re-delegations
of authority to positions of the affected
organizations in effect prior to this date
shall continue in effect in them or their
successors.
Dated: December 20, 2007.
Michael O. Leavitt,
Secretary.
[FR Doc. 07–6257 Filed 12–31–07; 8:45 am]
BILLING CODE 4160–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D–0492]
Guidance for Industry and Food and
Drug Administration; Interactive
Review for Medical Device
Submissions: 510(k)s, Original PMAs,
PMA Supplements, Original BLAs, and
BLA Supplements; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Interactive Review for Medical Device
Submissions: 510(k)s, Original PMAs,
PMA Supplements, Original BLAs, and
BLA Supplements.’’ The purpose of this
guidance document is to recommend an
E:\FR\FM\02JAN1.SGM
02JAN1
Federal Register / Vol. 73, No. 1 / Wednesday, January 2, 2008 / Notices
pwalker on PROD1PC71 with NOTICES
interactive premarket review process for
these submissions that is designed to
expedite FDA’s review of device
applications while continuing to assure
device safety and effectiveness, in
accordance with the goals of the Food
and Drug Administration Amendments
Act of 2007 (FDAAA).
DATES: Submit written or electronic
comments on this guidance at any time.
General comments on agency guidelines
are welcome at any time.
ADDRESSES: Submit written requests for
single copies of the guidance document
entitled ‘‘Interactive Review for Medical
Device Submissions: 510(k)s, Original
PMAs, PMA Supplements, Original
BLAs, and BLA Supplements’’ to the
Division of Small Manufacturers,
International, and Consumer Assistance
(HFZ–220), Center for Devices and
Radiological Health, Food and Drug
Administration, 1350 Piccard Dr.,
Rockville, MD 20850. Send one selfaddressed adhesive label to assist that
office in processing your request, or fax
your request to 240–276–3151. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance.
Submit written comments concerning
this guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to either https://
www.fda.gov/dockets/ecomments or
https://www.regulations.gov. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Samie Allen, Center for Devices and
Radiological Health (HFZ–402), Food
and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850,
240–276–4013.
SUPPLEMENTARY INFORMATION:
I. Background
In the letter from the Secretary of
Health and Human Services to the
Chairman of the Committee on Health,
Education, Labor, and Pensions of the
Senate setting out the goals of the
Medical Device User Fee Amendments
of 2007 (MDUFA) (see section 201(c) of
FDAAA), dated September 27, 2007,
FDA committed to developing a
guidance document that describes an
interactive review process between FDA
and industry for specific medical device
premarket submissions. While FDA
committed to developing an interactive
review process only for premarket
notification submissions (510(k)s),
premarket approval applications
(PMAs), and PMA supplements, the
VerDate Aug<31>2005
19:07 Dec 31, 2007
Jkt 214001
agency believes that medical device
Biologic License Applications (BLAs)
could also benefit from such a process.
Therefore, the guidance document also
applies to medical device BLAs and
BLA supplements.
The goal of the interactive review
process is to improve the timeliness of
the review process for 510(k)s, PMAs,
PMA supplements, BLAs and BLA
supplements. FDA expects that the
interactive review process will result in
prompter approvals and clearances of
medical devices and thereby improve
the public health. FDA intends to
reassess the interactive review process
on a regular basis to determine whether
it is meeting its intended objectives.
When necessary, changes will be
implemented to improve the efficiency
of this process.
FDA is making this guidance
document immediately in effect because
prior public participation was not
feasible or appropriate. In the letter
described in section 201(c) of FDAAA
that sets out the goals of MDUFA, FDA
committed to developing, within 3
months of the date of FDAAA’s
enactment, a guidance document that
describes an interactive review process.
The interactive review process supports
a less burdensome approach to the
premarket review process that is
consistent with public health.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on the interactive
review process for premarket medical
device submissions. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statute
and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by using the
Internet. To receive ‘‘Interactive Review
for Medical Device Submissions:
510(k)s, Original PMAs, PMA
Supplements, Original BLAs, and BLA
Supplements,’’ you may either send an
e-mail request to dsmica@fda.hhs.gov to
receive an electronic copy of the
document or send a fax request to 240–
276–3151 to receive a hard copy. Please
use the document number 1655 to
identify the guidance you are
requesting.
CDRH maintains an entry on the
Internet for easy access to information
including text, graphics, and files that
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
195
may be downloaded to a personal
computer with Internet access. Updated
on a regular basis, the CDRH home page
includes device safety alerts, Federal
Register reprints, information on
premarket submissions [including lists
of approved applications and
manufacturers’ addresses], small
manufacturer’s assistance, information
on video conferencing and electronic
submissions, Mammography Matters,
and other device-oriented information.
The CDRH web site may be accessed at
https://www.fda.gov/cdrh. A search
capability for all CDRH guidance
documents is available at https://
www.fda.gov/cdrh/guidance.html.
Guidance documents are also available
on the Division of Dockets Management
Internet site at https://www.fda.gov/
ohrms/dockets.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C.
§§ 3501–3520) (the PRA). The
collections of information in 21 CFR
part 807, subpart E, have been approved
under OMB control number 0910–0120;
the collections of information in 21 CFR
part 814, subpart B, have been approved
under OMB control number 0910–0231;
and the collections of information in 21
CFR part 601, subpart A, have been
approved under OMB control number
0910–0338.
V. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that in January 2008, the
FDA website is expected to transition to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. After the transition
date, electronic submissions will be
accepted by FDA through the FDMS
only. When the exact date of the
transition to FDMS is known, FDA will
publish a Federal Register notice
announcing that date.
E:\FR\FM\02JAN1.SGM
02JAN1
196
Federal Register / Vol. 73, No. 1 / Wednesday, January 2, 2008 / Notices
Dated: December 26, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 07–6268 Filed 12–27–07; 3:08 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D– 0496]
Draft Guidance for Industry on
Questions and Answers Regarding the
Labeling of Nonprescription Human
Drug Products Marketed Without an
Approved Application as Required by
the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act; Availability
AGENCY:
Food and Drug Administration,
HHS.
pwalker on PROD1PC71 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Questions and Answers Regarding the
Labeling of Nonprescription Human
Drug Products Marketed Without an
Approved Application as Required by
the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act.’’ This draft guidance is
intended to assist industry in complying
with the labeling requirements for
nonprescription (over-the-counter
(OTC)) human drugs marketed without
an approved application established by
the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act. Separate guidance,
issued by the Center for Food Safety and
Applied Nutrition on labeling
requirements for dietary supplements, is
announced elsewhere in this issue of
the Federal Register.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comments on this draft
guidance before it begins work on the
final version of the guidance, submit
written or electronic comments on the
draft guidance, including comments
regarding proposed collection of
information, by March 3, 2008.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
VerDate Aug<31>2005
19:07 Dec 31, 2007
Jkt 214001
Submit written comments on the draft
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, addressStreet5630
Fishers Lane, rm. 1061,
placeCityRockville, StateMD
PostalCode20852. Submit electronic
comments to https://www.fda.gov/
dockets/ecomments or https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT:
Walter Ellenberg, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 5488,
Silver Spring, MD 20993, 301–796–
2090.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance entitled ‘‘Questions and
Answers Regarding the Labeling of
Nonprescription Human Drug Products
Marketed Without an Approved
Application as Required by the Dietary
Supplement and Nonprescription Drug
Consumer Protection Act.’’ On
December 22, 2006, the President signed
into law the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act (Public Law 109–462,
120 Stat. 3469). This law amends the
Federal Food, Drug, and Cosmetic Act
(the act) with respect to serious adverse
event reporting for dietary supplements
and nonprescription drugs marketed
without an approved application. The
draft guidance document contains
questions and answers relating to the
new labeling requirements under Public
Law 109–462 for OTC drugs marketed
without an approved application.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on this topic. It does not create or confer
any rights for or on any person and does
not operate to bind FDA or the public.
An alternative approach may be used if
such approach satisfies the requirement
of the applicable statutes and
regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one copy.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that in January 2008, the
FDA Web site is expected to transition
to the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. After the transition
date, electronic submissions will be
accepted by FDA through the FDMS
only. When the exact date of the
transition to FDMS is known, FDA will
publish a Federal Register notice
announcing that date.
III. Paperwork Reduction Act of 1995
Under the Paperwork Reduction Act
of 1995 (the PRA) (44 U.S.C. 3501–
3520), Federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth as follows.
With respect to the following
collection of information, FDA invites
comment on the following: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection on respondents, including
through the use of automated collection
techniques, when appropriate, and other
forms of information technology.
Title: Labeling Requirements and
Recommendations under the Dietary
Supplement and Nonprescription Drug
Consumer Protection Act for
Nonprescription Drug Products
Marketed Without an Approved
Application.
E:\FR\FM\02JAN1.SGM
02JAN1
]]>Agencies
[Federal Register Volume 73, Number 1 (Wednesday, January 2, 2008)]
[Notices]
[Pages 194-196]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-6268]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D-0492]
Guidance for Industry and Food and Drug Administration;
Interactive Review for Medical Device Submissions: 510(k)s, Original
PMAs, PMA Supplements, Original BLAs, and BLA Supplements; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Interactive Review for Medical
Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original
BLAs, and BLA Supplements.'' The purpose of this guidance document is
to recommend an
[[Page 195]]
interactive premarket review process for these submissions that is
designed to expedite FDA's review of device applications while
continuing to assure device safety and effectiveness, in accordance
with the goals of the Food and Drug Administration Amendments Act of
2007 (FDAAA).
DATES: Submit written or electronic comments on this guidance at any
time. General comments on agency guidelines are welcome at any time.
ADDRESSES: Submit written requests for single copies of the guidance
document entitled ``Interactive Review for Medical Device Submissions:
510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA
Supplements'' to the Division of Small Manufacturers, International,
and Consumer Assistance (HFZ-220), Center for Devices and Radiological
Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD
20850. Send one self-addressed adhesive label to assist that office in
processing your request, or fax your request to 240-276-3151. See the
SUPPLEMENTARY INFORMATION section for information on electronic access
to the guidance.
Submit written comments concerning this guidance to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to either https://www.fda.gov/dockets/ecomments or https://
www.regulations.gov. Identify comments with the docket number found in
brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Samie Allen, Center for Devices and
Radiological Health (HFZ-402), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 240-276-4013.
SUPPLEMENTARY INFORMATION:
I. Background
In the letter from the Secretary of Health and Human Services to
the Chairman of the Committee on Health, Education, Labor, and Pensions
of the Senate setting out the goals of the Medical Device User Fee
Amendments of 2007 (MDUFA) (see section 201(c) of FDAAA), dated
September 27, 2007, FDA committed to developing a guidance document
that describes an interactive review process between FDA and industry
for specific medical device premarket submissions. While FDA committed
to developing an interactive review process only for premarket
notification submissions (510(k)s), premarket approval applications
(PMAs), and PMA supplements, the agency believes that medical device
Biologic License Applications (BLAs) could also benefit from such a
process. Therefore, the guidance document also applies to medical
device BLAs and BLA supplements.
The goal of the interactive review process is to improve the
timeliness of the review process for 510(k)s, PMAs, PMA supplements,
BLAs and BLA supplements. FDA expects that the interactive review
process will result in prompter approvals and clearances of medical
devices and thereby improve the public health. FDA intends to reassess
the interactive review process on a regular basis to determine whether
it is meeting its intended objectives. When necessary, changes will be
implemented to improve the efficiency of this process.
FDA is making this guidance document immediately in effect because
prior public participation was not feasible or appropriate. In the
letter described in section 201(c) of FDAAA that sets out the goals of
MDUFA, FDA committed to developing, within 3 months of the date of
FDAAA's enactment, a guidance document that describes an interactive
review process. The interactive review process supports a less
burdensome approach to the premarket review process that is consistent
with public health.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
agency's current thinking on the interactive review process for
premarket medical device submissions. It does not create or confer any
rights for or on any person and does not operate to bind FDA or the
public. An alternative approach may be used if such approach satisfies
the requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
using the Internet. To receive ``Interactive Review for Medical Device
Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs,
and BLA Supplements,'' you may either send an e-mail request to
dsmica@fda.hhs.gov to receive an electronic copy of the document or
send a fax request to 240-276-3151 to receive a hard copy. Please use
the document number 1655 to identify the guidance you are requesting.
CDRH maintains an entry on the Internet for easy access to
information including text, graphics, and files that may be downloaded
to a personal computer with Internet access. Updated on a regular
basis, the CDRH home page includes device safety alerts, Federal
Register reprints, information on premarket submissions [including
lists of approved applications and manufacturers' addresses], small
manufacturer's assistance, information on video conferencing and
electronic submissions, Mammography Matters, and other device-oriented
information. The CDRH web site may be accessed at https://www.fda.gov/
cdrh. A search capability for all CDRH guidance documents is available
at https://www.fda.gov/cdrh/guidance.html. Guidance documents are also
available on the Division of Dockets Management Internet site at http:/
/www.fda.gov/ohrms/dockets.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. Sec. Sec. 3501-
3520) (the PRA). The collections of information in 21 CFR part 807,
subpart E, have been approved under OMB control number 0910-0120; the
collections of information in 21 CFR part 814, subpart B, have been
approved under OMB control number 0910-0231; and the collections of
information in 21 CFR part 601, subpart A, have been approved under OMB
control number 0910-0338.
V. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Please note that in January 2008, the FDA website is expected to
transition to the Federal Dockets Management System (FDMS). FDMS is a
Government-wide, electronic docket management system. After the
transition date, electronic submissions will be accepted by FDA through
the FDMS only. When the exact date of the transition to FDMS is known,
FDA will publish a Federal Register notice announcing that date.
[[Page 196]]
Dated: December 26, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 07-6268 Filed 12-27-07; 3:08 pm]
BILLING CODE 4160-01-S
